Trimetazidine effects on oxidative damage

Research output: Contribution to journalArticle

Abstract

Trimetazidine is an anti anginal medication and ensures the proper functioning of transmembrane ionic channels by maintaining intracellular ATP production in ischemic conditions. Trimetazidine prevents the accumulation of calcium in cardiomyocytes, adjusts cellular acidosis, and decreases production of free oxygen radicals. Trimetazidine blocks long chain 3-ketoacyl coenzyme A thiolase activity, thereby shifting ATP production more towards glucose oxidation instead of fatty acid β-oxidation during myocardial ischemia. By inhibiting fatty acid β-oxidation, fewer free radicals are formed in the cardiomyocytes with more efficient oxygen consumption and ATP production, resulting in recovery of myocardial contractile function and inhibition of malignant arrhythmias. Moreover, cardiac enzymatic activities such as phosphorylase and ATPase increased significantly in ischemic areas with trimetazidine pretreatment before myocardial ischemia. Protective effects of trimetazidine by increasing ventricular fibrillation threshold during coronary artery occlusion were consistent in animal studies.

Original languageEnglish
Pages (from-to)27-29
Number of pages3
JournalHeart and Metabolism
Issue number60
Publication statusPublished - 2013 Sep 1

Fingerprint

Trimetazidine
Adenosine Triphosphate
Cardiac Myocytes
Free Radicals
Myocardial Ischemia
Fatty Acids
Phosphorylases
Coronary Occlusion
Ventricular Fibrillation
Coenzyme A
Acidosis
Ion Channels
Oxygen Consumption
Adenosine Triphosphatases
Cardiac Arrhythmias
Reactive Oxygen Species
Coronary Vessels
Calcium
Glucose

Keywords

  • Myocardial infarction
  • Oxidative damage
  • Trimetazidine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Trimetazidine effects on oxidative damage. / Hong, Soon Jun.

In: Heart and Metabolism, No. 60, 01.09.2013, p. 27-29.

Research output: Contribution to journalArticle

@article{84d47fbea67743fe9ae47e1719359575,
title = "Trimetazidine effects on oxidative damage",
abstract = "Trimetazidine is an anti anginal medication and ensures the proper functioning of transmembrane ionic channels by maintaining intracellular ATP production in ischemic conditions. Trimetazidine prevents the accumulation of calcium in cardiomyocytes, adjusts cellular acidosis, and decreases production of free oxygen radicals. Trimetazidine blocks long chain 3-ketoacyl coenzyme A thiolase activity, thereby shifting ATP production more towards glucose oxidation instead of fatty acid β-oxidation during myocardial ischemia. By inhibiting fatty acid β-oxidation, fewer free radicals are formed in the cardiomyocytes with more efficient oxygen consumption and ATP production, resulting in recovery of myocardial contractile function and inhibition of malignant arrhythmias. Moreover, cardiac enzymatic activities such as phosphorylase and ATPase increased significantly in ischemic areas with trimetazidine pretreatment before myocardial ischemia. Protective effects of trimetazidine by increasing ventricular fibrillation threshold during coronary artery occlusion were consistent in animal studies.",
keywords = "Myocardial infarction, Oxidative damage, Trimetazidine",
author = "Hong, {Soon Jun}",
year = "2013",
month = "9",
day = "1",
language = "English",
pages = "27--29",
journal = "Heart and Metabolism",
issn = "1566-0338",
publisher = "Imprimerie Jouve",
number = "60",

}

TY - JOUR

T1 - Trimetazidine effects on oxidative damage

AU - Hong, Soon Jun

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Trimetazidine is an anti anginal medication and ensures the proper functioning of transmembrane ionic channels by maintaining intracellular ATP production in ischemic conditions. Trimetazidine prevents the accumulation of calcium in cardiomyocytes, adjusts cellular acidosis, and decreases production of free oxygen radicals. Trimetazidine blocks long chain 3-ketoacyl coenzyme A thiolase activity, thereby shifting ATP production more towards glucose oxidation instead of fatty acid β-oxidation during myocardial ischemia. By inhibiting fatty acid β-oxidation, fewer free radicals are formed in the cardiomyocytes with more efficient oxygen consumption and ATP production, resulting in recovery of myocardial contractile function and inhibition of malignant arrhythmias. Moreover, cardiac enzymatic activities such as phosphorylase and ATPase increased significantly in ischemic areas with trimetazidine pretreatment before myocardial ischemia. Protective effects of trimetazidine by increasing ventricular fibrillation threshold during coronary artery occlusion were consistent in animal studies.

AB - Trimetazidine is an anti anginal medication and ensures the proper functioning of transmembrane ionic channels by maintaining intracellular ATP production in ischemic conditions. Trimetazidine prevents the accumulation of calcium in cardiomyocytes, adjusts cellular acidosis, and decreases production of free oxygen radicals. Trimetazidine blocks long chain 3-ketoacyl coenzyme A thiolase activity, thereby shifting ATP production more towards glucose oxidation instead of fatty acid β-oxidation during myocardial ischemia. By inhibiting fatty acid β-oxidation, fewer free radicals are formed in the cardiomyocytes with more efficient oxygen consumption and ATP production, resulting in recovery of myocardial contractile function and inhibition of malignant arrhythmias. Moreover, cardiac enzymatic activities such as phosphorylase and ATPase increased significantly in ischemic areas with trimetazidine pretreatment before myocardial ischemia. Protective effects of trimetazidine by increasing ventricular fibrillation threshold during coronary artery occlusion were consistent in animal studies.

KW - Myocardial infarction

KW - Oxidative damage

KW - Trimetazidine

UR - http://www.scopus.com/inward/record.url?scp=84891953210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891953210&partnerID=8YFLogxK

M3 - Article

SP - 27

EP - 29

JO - Heart and Metabolism

JF - Heart and Metabolism

SN - 1566-0338

IS - 60

ER -